Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2024 Dec;296(6):481-494.
doi: 10.1111/joim.20017. Epub 2024 Oct 10.

Romosozumab versus denosumab in long-term users of glucocorticoids: A pilot randomized controlled trial

Chi Chiu Mok  1 , Kar Li Chan  1 , Sau Mei Tse  1 , Sammy Pak Lam Chen  2 , Kathryn Choon Beng Tan  3 , Wai Han Ma  4
Affiliations
Randomized Controlled Trial

Romosozumab versus denosumab in long-term users of glucocorticoids: A pilot randomized controlled trial

Chi Chiu Mok et al. J Intern Med. 2024 Dec.

Abstract

Objective: To compare the efficacy of romosozumab (ROMO) and denosumab (DEN) in prevalent long-term glucocorticoid (GC) users.

Methods: Adult patients receiving oral prednisolone (≥5 mg/day) with high risk of fracture were randomized to receive subcutaneous ROMO (210 mg monthly) or DEN (60 mg 6-monthly) for 12 months, followed by DEN for two more doses. The primary end point was the change in spine bone mineral density (BMD) from Months 0 to 12. Secondary end points included changes in BMD of the spine/hip/femoral neck and bone turnover markers at various time points and adverse events.

Results: Seventy patients (age 62.6 ± 9.1 years; 96% women; median prednisolone dose 5.0 mg/day; duration of therapy 10.7 ± 7.4 years) were enrolled, and 63 completed the study. At Month 12, the spine BMD increased significantly in both ROMO (+7.3% ± 4.5%; p < 0.001) and DEN (+2.3% ± 3.1%; p < 0.001) groups. The absolute spine BMD gain from Months 0 to 12 was significantly greater in ROMO-treated patients (p < 0.001). Although the total hip BMD at Month 12 also increased significantly in the ROMO (+1.6% ± 3.3%; p = 0.01) and DEN groups (+1.6% ± 2.6%; p = 0.003), the absolute BMD gain was not significantly different between the groups. At Month 24, the spine BMD continued to increase in both the ROMO (+9.7% ± 4.8%; p < 0.001) and DEN group (+3.0% ± 3.0%; p < 0.001) compared to baseline, and the absolute BMD gain remained significantly greater in ROMO-treated patients. The total hip BMD continued to increase in both groups (ROMO +2.9% ± 3.7%; p < 0.001; DEN +2.2% ± 3.4%; p = 0.001), but the changes from baseline were similar. Injection site reaction was more frequently reported in ROMO-treated patients.

Conclusion: ROMO was superior to DEN in raising the spine BMD at Month 12 in chronic GC users. After switching to DEN, ROMO-treated patients continued to gain spine BMD to a greater extent than DEN until Month 24.

Keywords: denosumab; glucocorticoids; osteoporosis; romosozumab.

PubMed Disclaimer

References

    1. Kaji H, Yamauchi M, Chihara K, Sugimoto T. The threshold of bone mineral density for vertebral fracture in female patients with glucocorticoid‐induced osteoporosis. Endocr J. 2006;53:27–34.
    1. Angeli A, Guglielmi G, Dovio A, Capelli G, de Feo D, Giannini S, et al. High prevalence of asymptomatic vertebral fractures in postmenopausal women receiving chronic glucocorticoid therapy: a cross‐sectional outpatient study. Bone. 2006;39:253–259.
    1. Villa P, Moruzzi MC, Lassandro AP, Leoni F, Di Nardo F, De Waure C, et al. Glucocorticoid therapy as a significant risk factor for osteoporosis and fractures in an Italian postmenopausal population. Gynecol Endocrinol. 2013;29:678–682.
    1. van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C. Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (Oxford). 2000;39:1383–1389.
    1. De Vries F, Bracke M, Leufkens HGM, Lammers JWJ, Cooper C, Van Staa TP. Fracture risk with intermittent high‐dose oral glucocorticoid therapy. Arthritis Rheum. 2007;56:208–214.

Publication types

MeSH terms

LinkOut - more resources